Physician profile
James A Sheerer
NPI 1275501819
$12,812.44
in general payments reported to CMS, 2019-2025
51 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,598 · 2020: $463 · 2021: $931 · 2022: $2,551 · 2023: $3,238 · 2024: $2,261 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,269.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,183.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,760.70 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $1,446.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,093.27 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,055.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $922.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $591.56 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.27 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.98 | 2019-2025 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $258.10 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $227.18 | 2022 | |
| Merck Sharp & Dohme LLC | $208.89 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $206.36 | 2023-2024 | |
| Dexcom, INC. | $197.83 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $176.97 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sheerer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.